V Square Quantitative Management LLC Has $301,000 Stock Position in Solventum Co. (NYSE:SOLV)

V Square Quantitative Management LLC reduced its stake in shares of Solventum Co. (NYSE:SOLV) by 5.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,558 shares of the company’s stock after selling 280 shares during the period. V Square Quantitative Management LLC’s holdings in Solventum were worth $301,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of SOLV. Exchange Traded Concepts LLC acquired a new stake in Solventum during the 3rd quarter worth approximately $60,000. Blue Trust Inc. acquired a new stake in shares of Solventum in the third quarter valued at approximately $538,000. Copeland Capital Management LLC acquired a new stake in shares of Solventum in the third quarter valued at approximately $26,000. Foundations Investment Advisors LLC acquired a new stake in shares of Solventum in the third quarter valued at approximately $345,000. Finally, Sequoia Financial Advisors LLC raised its holdings in shares of Solventum by 8.3% in the third quarter. Sequoia Financial Advisors LLC now owns 5,737 shares of the company’s stock valued at $400,000 after purchasing an additional 441 shares during the last quarter.

Solventum Price Performance

NYSE:SOLV opened at $74.04 on Monday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a fifty day simple moving average of $70.75 and a 200 day simple moving average of $68.58.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of recent research reports. Morgan Stanley lifted their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Mizuho initiated coverage on shares of Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective on the stock. Finally, Piper Sandler lifted their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.